|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/4985 | |
| C07D 471/04 | |||
| A61K 31/7072 | |||
| A61K 31/522 |
| (11) | Number of the document | 3229804 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15867817.7 |
| Date of filing the European patent application | 2015-12-04 | |
| (97) | Date of publication of the European application | 2017-10-18 |
| (45) | Date of publication and mention of the grant of the patent | 2020-05-06 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2015/063851 |
| Date | 2015-12-04 |
| (87) | Number | WO 2016/094198 |
| Date | 2016-06-16 |
| (30) | Number | Date | Country code |
| 201462089570 P | 2014-12-09 | US |
| (72) |
GRAHAM, Thomas, H., US
EMBREY, Mark, W., US
WALJI, Abbas, US
WADDELL, Sherman, T., US
|
| (73) |
Merck Sharp & Dohme Corp.,
126 East Lincoln Avenue, Rahway, NJ 07065-0907,
US
|
| (54) | SPIROCYCLIC HETEROCYCLE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS |
| SPIROCYCLIC HETEROCYCLE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS |